Evidence map›Paper›PMID 34483510›Full record

ReviewJournal of obstetrics and gynaecology of India2021

Recent Advances in Diagnosis and Management of Female Genital Tuberculosis.

J B Sharma, Eshani Sharma, Sangeeta Sharma, Sona Dharmendra

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of obstetrics and gynaecology of India, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

J B SharmaDepartment of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Room No. 3064A, IIIrd Floor, Teaching Block, New Delhi, 110029 India.ORCID 0000-0001-5608-3675
Eshani SharmaDepartment of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Room No. 3064A, IIIrd Floor, Teaching Block, New Delhi, 110029 India.
Sangeeta SharmaDepartment of Paediatrics, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India.
Sona DharmendraDepartment of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Room No. 3064A, IIIrd Floor, Teaching Block, New Delhi, 110029 India.
All India Institute of Medical Sciences · INLRS Institute of Tuberculosis and Respiratory Diseases · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Female genital tuberculosis (FGTB) is an important cause of significant morbidity and infertility. Gold-standard diagnosis by demonstration of acid fast bacilli on microscopy or culture or detection of epithelioid granuloma on histopathology of endometrial or peritoneal biopsy is positive in only small percentage of cases due to its paucibacillary nature. Use of gene Xpert on endometrial or peritoneal biopsy has improved sensitivity of diagnosis. Composite reference standard (CRS) is a significant landmark in its diagnosis in which combination of factors like AFB on microscopy or culture, positive gene Xpert, epithelioid granuloma on endometrial or peritoneal biopsy, demonstration of definite or probable findings of FGTB on laparoscopy or hysteroscopy. There have been many advances and changes in management of FGTB recently. The program is now called National Tuberculosis Elimination Program (NTEP), and categorization of TB has been stopped. Now, patients are divided into drug-sensitive FGTB for which rifampicin (R), isoniazid (H), pyrazinamide (Z) and ethambutol (E) are given orally daily for 2 months followed by three drugs (rifampicin, isoniazid and ethambutol (RHE) orally daily for next 4 months. Multi-drug-resistant FGTB is treated with shorter MDR TB regimen of 9-11 months or longer MDR TB regimen of 18-20 months with reserved drugs. In vitro fertilization and embryo transfer have good results for blocked tubes and receptive endometrium, while surrogacy or adoption is advised for severe grades of Asherman's syndrome.

Indexed as

Composite reference standardDrug-resistant TBDrug-sensitive tuberculosisFemale genital tuberculosisHysteroscopyLaparoscopy

Identifiers

PMID34483510
PMCPMC8402974
OpenAlexW3196331037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.